AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
Enrollment Ongoing in Phase 2/3 Pivotal Trial of Epetraborole in Treatment- Refractory MAC Lung Disease…
News
PDS Biotech to Present at the LD Micro Main Event XV
FLORHAM PARK, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a…
Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting
WILMETTE, Ill., Oct. 19, 2022 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical…
Cocrystal Pharma to Present at the LD Micro Main Event XV
BOTHELL, Wash., Oct. 19, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that…
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022
— Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological…
Nephros Third Quarter 2022 Financial Results Conference Call
SOUTH ORANGE, NJ, Oct. 19, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Nephros, Inc. (Nasdaq:…
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
Highlighting Ocugen research and innovative technologies Featuring thought leaders in gene therapy and vaccines MALVERN,…
Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
NEW YORK and CLEVELAND, Oct. 19, 2022 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO)…
Sinaptica Therapeutics Announces FDA Breakthrough Device Designation for its Novel Noninvasive Neurostimulation Treatment for Alzheimer’s Disease
SinaptiStim™ – AD System provides personalized and precision-delivered electromagnetic therapeutic approach to treating cognitive and…
Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022
BEDMINSTER, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB),…
Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
BOSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company…
Tonix Pharmaceuticals to Present at the 2022 ThinkEquity Conference
CHATHAM, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a…
Kamada Awarded $22 Million Extension of Canadian Supply Tender
Awarded Extension to Existing Supply Tender which relates to Portfolio of Four Specialty IgG Products…
VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388
– Study reveals the structural basis of receptor activation and signaling by IL-27 cytokine –– Study…
IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022
BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) — IsoPlexis Corporation (Nasdaq: ISO), a company empowering…
Breckenridge Distillery Announces Ultimate Whiskey and Beer Collaboration With Breckenridge Brewery
Two Breckenridge Staples Launch Second Annual Buddy Pass, Limited-Edition Whiskey and Beer Across the U.S….
Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress
ReSPECT-LM Phase 1 clinical trial selected as TOP Trials Oral Presentation Treatment was well tolerated…
Gritstone to Host Data Update on CORAL and Discuss the Application of Self-amplifying mRNA (samRNA) in Infectious Diseases
— Data to be presented from CORAL-BOOST and CORAL-CEPI trials evaluating Gritstone’s samRNA vaccine candidates…
Tiziana Life Sciences Ltd Invites You to Join Us at The ThinkEquity Conference
NEW YORK, Oct. 19, 2022 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd (NASDAQ: TLSA), a biotechnology…
Cerevel Therapeutics to Report Third Quarter 2022 Financial Results and Pipeline Update on Tuesday, November 8, 2022
CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) — Cerevel Therapeutics (Nasdaq: CERE), a company dedicated…